Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Ongoing Initiated Jan 12, 2024 (3 years ago)

Neptune's Fix

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Marketed without an approved NDA/ANDA: Product contains tianeptine, a substance not FDA-approved for any medical use in the United States.

Cause type: Unapproved drug

The product was marketed without an approved NDA/ANDA, or does not meet the OTC monograph it claims to follow. Nothing about the product - dose, purity, safety - has been reviewed by FDA, so the claims on the box are unverified. All unapproved drug recalls.

What was recalled

Neptune's Fix, Tianeptine Extra Strength Elixir, 0.338 fl oz (10 mL) bottle, Distributed By Neptune Resources, LLC, 30 N. Gould Street, Ste R, Sheridan, WY 82801.

Recalling firm
Neptune Resources, LLC
Origin
MO, United States
Initiated by
Voluntary: Firm initiated
Company announcement
Jan 28, 2024 · FDA notice with lot numbers
FDA recall number
D-0334-2024 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week.

Other recalls by Neptune Resources, LLC

All 2024 recalls
Class I · High risk

Neptune's Fix

Marketed without an approved NDA/ANDA: Product contains tianeptine, a substance not FDA-approved for any medical use in the United States.

Ongoing Unapproved drug Neptune Resources, LLC D-0335-2024
Class I · High risk

Neptune's Fix

Marketed without an approved NDA/ANDA: Product contains tianeptine, a substance not FDA-approved for any medical use in the United States.

Ongoing Unapproved drug Neptune Resources, LLC D-0333-2024

Other unapproved drug recalls from 2024

All unapproved drug recalls
Class II · Moderate risk

Ramipril Capsules USP 10 mg

CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor

Terminated Unapproved drug Lupin Pharmaceuticals Inc. NDC 68180-591-09 D-0054-2025
Class II · Moderate risk

Ramipril Capsules USP 5 mg

CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor

Terminated Unapproved drug Lupin Pharmaceuticals Inc. NDC 68180-590-09 D-0053-2025
Class II · Moderate risk

Ramipril Capsules USP 2.5 mg

CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor

Terminated Unapproved drug Lupin Pharmaceuticals Inc. NDC 68180-589-09 D-0052-2025